Abstract
New antifibrotic therapies do not impair the clinical course and survival in patients with ILD who underwent DLuTX
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Ius has nothing to disclose.
Conflict of interest: Dr. Tudorache has nothing to disclose.
Conflict of interest: Ms Boehm has nothing to disclose.
Conflict of interest: Dr. Jaksch has nothing to disclose.
Conflict of interest: Dr. Klepetko has nothing to disclose.
Conflict of interest: Dr. Lambers reports other from Boehringer Ingelheim, other from Roche, outside the submitted work.
Conflict of interest: Dr. Lee has nothing to disclose.
Conflict of interest: Dr. Ristl has nothing to disclose.
Conflict of interest: Dr. Welte reports grants from Boehringer and Roche during the conduct of the study; personal fees from Boehringer and from Roche outside the submitted work; .
Conflict of interest: Jens Gottlieb
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018